R. Desai

发表

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Thomas C. Chen, F. Lieberman, R. Stupp, 2015, JAMA.

DNA sequence analysis and comparison of the variable heavy and light chain regions of two IgM, monoclonal, anti-myelin associated glycoprotein antibodies

R. Desai, N. Latov, L. Spatz, 1992, Journal of Neuroimmunology.

Molecular cloning of a human immunoglobulin heavy chain variable (V H ) region with anti-myelin-associated glycoprotein activity

F. Alt, E. Kabat, R. Desai, 1990, Journal of Neuroimmunology.

Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas.

J. Bruce, R. Desai, J. P. Johnson, 1996, Neurosurgery.

MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.

B. Tycko, J. Bruce, R. Desai, 1995, The American journal of pathology.

Cloning and sequence analysis of the VH and VL regions of an anti-myelin/DNA antibody from a patient with peripheral neuropathy and chronic lymphocytic leukemia.

F. Alt, R. Desai, J. Golier, 1990, Journal of immunology.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial

Thomas C. Chen, R. Stupp, M. Taphoorn, 2018, JAMA oncology.

Pathological Angiogenesis: An Overview

R. Desai, P. Brooks, R. Friesel, 2014 .

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial

R. Stupp, M. Taphoorn, S. Toms, 2018, JAMA oncology.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

F. Lieberman, R. Stupp, S. Toms, 2015, JAMA.